IDH2 and glioblastoma: The question remains whether patients with IDH wild-type malignant astrocytomas without histological evidence of necrosis and/or vascular proliferation, i.e. with AA IDH-wt, do not differ prognostically under the same therapy from patients diagnosed with GBM IDH-wt.